Clinical trials: Locally Advanced Colorectal Cancer
Rectal Cancer
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal…
- Trial name
- NCT06304545
- Testing
- Camrelizumab, Chemotherapy, Radiotherapy
- Volunteers
- 48 people
- Sponsor
- Harbin Medical University
Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk…
- Trial name
- NCT04495088
- Testing
- mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant)
- Where
- Germany
- Volunteers
- 215 people
- Sponsor
- Ralf Hofheinz
Rectal Cancer
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
This study is a one-year, observational, prospective cohort study. For enrolled patients with newly diagnosed locally advanced rectal cancer, the treatment plan will be decided by the physician based on the 2022 NCCN Rectal…
- Trial name
- NCT07346729
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer
Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer
The goal of this laboratory research is to look for genes that can predict which patients will achieve a complete disappearance of their colorectal cancer after treatment like chemotherapy, radiation, or other therapy.
- Trial name
- NCT02877056
- Testing
- Endoscopy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid…
- Trial name
- NCT07545356
- Testing
- KIVU-305
- Where
- 3 sites in Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Adenocarcinoma of Rectum
Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients
Statins are widely used as lipid-lowering agents to lower cardiovascular risk with a favorable safety profile. In our recent in vitro study, the addition of simvastatin to chemoradiotherapy with 5-FU showed synergistic anticancer…
- Trial name
- NCT02161822
- Testing
- simvastatin
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Colon and Rectal Cancer
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
- Trial name
- GAP Cemi (NCT07433673)
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Rectal Cancer, Advanced Solid Tumor
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
- Trial name
- NCT06577194
- Testing
- Sintilimab + IL-2 Combined with CAPOX, Short-course radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Rectal Cancer
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
The treatment protocol proposed in this study is to perform short-term radiation therapy and 4 cycles of FOLFOX chemotherapy for neoadjuvant treatment of locally advanced rectal cancer.
- Trial name
- SOLAR (NCT05673772)
- Testing
- short-course radiotherapy, mFOLFOX6, Chemoradiotherapy
- Where
- 9 sites in South Korea
- Volunteers
- 364 people
- Sponsor
- Kyungpook National University Hospital
Locally Advanced or Metastatic CRC
Phase II Clinical Study of LTC004 in Patients With mCRC
This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I.
- Trial name
- NCT06384235
- Testing
- LTC004
- Volunteers
- 30 people
- Sponsor
- Letolab
CRC (Colorectal Cancer), Melanoma (Skin Cancer)
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with…
- Conditions
- CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- TGI5 (NCT07376707)
- Testing
- TGI-5
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
Rectal Cancer, Locally Advanced Rectal Cancer
Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer
The current trial is evaluating the impact of deep regional hyperthermia on the pathological complete response rate in locally advanced rectal cancer in the context of preoperative 5FU based radiochemotherapy.
- Conditions
- Rectal Cancer, Locally Advanced Rectal Cancer, Hyperthermia, Hyperthermic Radiochemotherapy
- Trial name
- HT01 (NCT02353858)
- Testing
- Deep regional hyperthermia, Radiotherapy, Chemotherapy (5-Fluorouracil)
- Where
- Germany
- Volunteers
- 78 people
- Sponsor
- University Hospital Tuebingen
Locally Advanced Colorectal Carcinoma
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
The goal of this clinical trial is to compare the efficacy and safety of the combination of immune checkpoint inhibitors (ICIs) and FOLFOX regimen compared to FOLFOX regimen alone in the neoadjuvant chemotherapy of locally…
- Trial name
- NCT06154538
- Testing
- Immune checkpoint inhibitor, FOLFOX regimen
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00551421
- Testing
- pertuzumab, cetuximab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as mitomycin, fluorouracil, and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068744
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 24 sites in Belgium, Egypt and 5 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
- Trial name
- PUMA (NCT05131919)
- Testing
- Pembrolizumab
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute
DMMR Colorectal Cancer, MSI-H Colorectal Cancer
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also recommended as an alternative choice for…
- Conditions
- DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer
- Trial name
- NCT04301557
- Testing
- PD-1 Antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
"Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.
Among patients treated for locally advanced rectal cancer with neo-adjuvant radio-chemotherapy, about 15% will have complete clinical response in terms of no visible tumor or ulcerations on the site of the primary tumor, or…
- Trial name
- NORWAIT (NCT03402477)
- Where
- 7 sites in Norway
- Volunteers
- 86 people
- Sponsor
- Helse Stavanger HF
Colon Cancer, Neoadjuvant Therapies
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Most colorectal cancers belong to the microsatellite stable (MSS) or proficient mismatch repair (pMMR) subtypes, with limited response to PD-1 inhibitors.
- Conditions
- Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiation Therapy
- Trial name
- MODIFI-L (NCT07279077)
- Testing
- Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University